ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $62,303 | -57.7% | 39,149 | +65.7% | 0.00% | – |
| Q4 2022 | $147,451 | +189.1% | 23,630 | +209.1% | 0.00% | – |
| Q3 2022 | $51,000 | +18.6% | 7,645 | +12.0% | 0.00% | – |
| Q2 2022 | $43,000 | +38.7% | 6,827 | +1.2% | 0.00% | – |
| Q1 2022 | $31,000 | +106.7% | 6,745 | +115.0% | 0.00% | – |
| Q4 2021 | $15,000 | -89.7% | 3,137 | -73.9% | 0.00% | – |
| Q3 2021 | $145,000 | -64.3% | 12,026 | -37.4% | 0.00% | – |
| Q2 2021 | $406,000 | -31.0% | 19,208 | -8.3% | 0.00% | – |
| Q1 2021 | $588,000 | +18.8% | 20,939 | +9.9% | 0.00% | – |
| Q4 2020 | $495,000 | -30.2% | 19,054 | -0.2% | 0.00% | – |
| Q3 2020 | $709,000 | -31.7% | 19,090 | -5.6% | 0.00% | -100.0% |
| Q2 2020 | $1,038,000 | +97.0% | 20,230 | +21.1% | 0.00% | – |
| Q1 2020 | $527,000 | -50.5% | 16,709 | -6.4% | 0.00% | -100.0% |
| Q4 2019 | $1,064,000 | +183.0% | 17,850 | +73.9% | 0.00% | – |
| Q3 2019 | $376,000 | -21.2% | 10,267 | 0.0% | 0.00% | – |
| Q2 2019 | $477,000 | +21.7% | 10,267 | +5.1% | 0.00% | – |
| Q1 2019 | $392,000 | -9.7% | 9,769 | +3.7% | 0.00% | – |
| Q4 2018 | $434,000 | +38.7% | 9,416 | +33.3% | 0.00% | – |
| Q3 2018 | $313,000 | +13.0% | 7,066 | 0.0% | 0.00% | – |
| Q2 2018 | $277,000 | -43.2% | 7,066 | +4.7% | 0.00% | – |
| Q1 2018 | $488,000 | +67.7% | 6,751 | +53.9% | 0.00% | – |
| Q4 2017 | $291,000 | +29.3% | 4,388 | -3.1% | 0.00% | – |
| Q3 2017 | $225,000 | +17.2% | 4,530 | +11.7% | 0.00% | – |
| Q2 2017 | $192,000 | +35.2% | 4,054 | 0.0% | 0.00% | – |
| Q1 2017 | $142,000 | +167.9% | 4,054 | -2.6% | 0.00% | – |
| Q4 2016 | $53,000 | +76.7% | 4,161 | +90.3% | 0.00% | – |
| Q3 2016 | $30,000 | +36.4% | 2,187 | 0.0% | 0.00% | – |
| Q2 2016 | $22,000 | -40.5% | 2,187 | 0.0% | 0.00% | – |
| Q1 2016 | $37,000 | -24.5% | 2,187 | 0.0% | 0.00% | – |
| Q4 2015 | $49,000 | +11.4% | 2,187 | 0.0% | 0.00% | – |
| Q3 2015 | $44,000 | -74.7% | 2,187 | 0.0% | 0.00% | – |
| Q2 2015 | $174,000 | – | 2,187 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |